[Clinical evaluation of cefixime in children].
A new beta-lactamase-stable oral cephem antibiotic, cefixime (CFIX), was evaluated for safety, efficacy and pharmacokinetics in children. CFIX was effective in 19 of 20 cases (95%) with bacterial infections. The drug was especially effective against the cases of pneumonia due to beta-lactamase-producing H. influenzae or B. catarrhalis. Pharmacokinetic parameters of CFIX (3 mg/kg) with premeal administration were as follows: Kel 0.328 +/- 0.066 hr-1, T 1/2 2.14 +/- 0.36 hrs, AUC 10.9 +/- 8.7 micrograms X hr/ml, and Vd/F 1.64 +/- 1.42 L/kg. In most of the cases tested, the urinary excretion rate in 12 hours was 5 to 17%. A dose of 3 mg/kg twice daily seems to be adequate for a regular treatment.
D001424:Bacterial Infections / Q000188:drug therapy*; D020682:Cefixime; D002439:Cefotaxime / Q000031:analogs & derivatives* / Q000378:metabolism / Q000494:pharmacology / Q000627:therapeutic use; D002648:Child; D002675:Child, Preschool; D005260:Female; D006192:Haemophilus Infections / Q000188:drug therapy; D006801:Humans; D007223:Infant; D007700:Kinetics; D008297:Male; D011014:Pneumonia / Q000188:drug therapy; D011019:Pneumonia, Mycoplasma / Q000188:drug therapy; D012141:Respiratory Tract Infections / Q000188:drug therapy*; D014552:Urinary Tract Infections / Q000188:drug therapy*
D020682:Cefixime; D002439:Cefotaxime